title: How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?
abstract: BACKGROUND
  : It remains unclear how many sentinel lymph nodes (SLNs) must be removed to accurately predict lymph node status during SLN dissection in breast cancer. The objective of this study was to determine how many SLNs need to be removed for accurate lymph node staging and which patient and tumor characteristics influence this number.
  
  
  METHODS
  : The authors reviewed data for all patients in their prospective database with clinical tumor, lymph node, metastasis (TNM) T1 through T3, N0, M0 breast cancer who underwent lymphatic mapping at their institution during the years 1994 through 2006. There were 777 patients who had at least 1 SLN that was positive for cancer. Simple and multiple quantile regression analyses were used to determine which patient and tumor characteristics were associated with the number of positive SLNs. The baseline number of SLNs that needed to be dissected for detection of 99% of positive SLNs in the total group of patients also was determined.
  
  
  RESULTS
  : The mean number of SLNs removed in the 777 lymph node-positive patients was 2.9 (range, 1-13 SLNs). Greater than 99% of positive SLNs were identified in the first 5 lymph nodes removed. On univariate analysis, tumor histology, patient race, tumor location, and tumor size significantly affected the number of SLNs that needed to be removed to identify 99% of all positive SLNs. On multivariate analysis, mixed ductal and lobular histology, Caucasian race, inner quadrant tumor location, and T1 tumor classification significantly increased the number of SLNs that needed to be removed to achieve 99% recovery of all positive SLNs.
  
  
  CONCLUSIONS
  : In general, the removal of a maximum of 5 SLNs at surgery allowed for the recovery of >99% of positive SLNs in patients with breast cancer. The current findings indicated that tumor histology, patient race, and tumor size and location may influence this number.
authors.affiliation: Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Min
authors.initials: M
authors.lastname: Yi
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: Jeri S
authors.initials: JS
authors.lastname: Akins
authors.forename: Rosa F
authors.initials: RF
authors.lastname: Hwang
authors.forename: Anthony
authors.initials: A
authors.lastname: Lucci
authors.forename: Henry M
authors.initials: HM
authors.lastname: Kuerer
authors.forename: Gildy V
authors.initials: GV
authors.lastname: Babiera
authors.forename: Michael Z
authors.initials: MZ
authors.lastname: Gilcrease
authors.forename: Kelly K
authors.initials: KK
authors.lastname: Hunt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D008207:Lymphatic Metastasis; D008875:Middle Aged; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*